THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Bernstein analyst Courtney Breen maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $380.00. Courtney Breen has given his Buy rating due to a ...

TD Cowen raised the firm’s price target on Amgen (AMGN) to $383 from $381 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 ...

Strategic acquisitions and pipeline expansions remain central to future growth plans. Amgen revealed a positive third quarter of 2024, exceeding earnings expectations. Despite some challenges in ...

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? Risk aversion swept across markets on Thursday as investor disappointment ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug maker’s clutch of approved therapies under its fold. With Horizon ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of ...